Skip to content
DilutionScan
Arcturus Therapeutics Holdings Inc. logo
ARCT$8.04+0.88%

Arcturus Therapeutics Holdings Inc.

Sector: Pharmaceutical PreparationsIndustry: BiotechnologyCountry: USExchange: Nasdaq

Mkt Cap & EV$251.56M /
Float & O/SPro
Est. Net Cash/Sh
Inst OwnPro

DilutionScan read 28 of Arcturus Therapeutics Holdings Inc.'s SEC filings and found 1 ATM program, 2 shelf registrations and 3 completed offerings on file for ARCT. The latest dilution event on file is an offering on Nov 16, 2026. Analysis updated Nov 18, 2026.

Signal8 Summary

ARCT

Unprofitable biotech with shrinking revenue

What's Happening Right Now

  • : Reported Q2 2026 revenue of $3.0 million, down from the prior year due to a collaboration wind-down, with a net loss of $23.8 million, but regained global rights to its KOSTAIVE COVID-19 vaccine and extended its cash runway through 2028.
  • : Announced a strategic collaboration with Thermo Fisher Scientific to support the Phase 3 development and potential commercialization of ARCT-032, its investigational mRNA therapy for cystic fibrosis.

Snapshot

Arcturus is an unprofitable biotech burning through cash to develop RNA medicines. Revenue dropped 51% in FY 2025 to $67.2M, resulting in a $65.8M net loss and a $74.3M free cash flow burn.

Create a free account to read the rest

Raise routes on file: active ATM + effective shelf · latest dilution event 2 days ago

Overall Risk
Offering Ability
Overhead Supply
Historical
Cash Need

AI dilution summary

The dominant contractual driver and its mechanism, then each further driver ranked.

Latest dilution event

Nov 16, 2026 · Offering

How we read filings

Every warrant, convertible, ATM and shelf, cited to the filing

A free account reads 3 tickers a day in full

Get Pro · every ticker

From $29.99/mo. Signal8 Pro is $49/mo, or $40.67/mo billed yearly ($488/yr)

Exchange compliance

Deficiency notices, days under the minimum bid price, grace periods and listing rules, free with an account.

Share count and cash history

Shares outstanding, potential dilution and cash over time

ATM · 1

What is this?

Capacity, sold to date and agent with Pro

ATM program

Issued 2022

Active

Total capacity

Sold to date

Remaining capacity
Sales agent
Agreement date
Commission
Filing link and full terms

Shelf · 2

What is this?

Capacity, dates and baby-shelf status with Pro

S-3 shelf registration

Issued 2025

Active

Total capacity

Remaining

Filed
Effective
Expires
Baby shelf
Filing link and full terms

S-3 shelf registration

Issued 2022

Superseded

Total capacity

Remaining

Filed
Effective
Expires
Baby shelf
Filing link and full terms

Offerings · 3

What is this?

Proceeds, price, shares and agent with Pro

PIPE

Issued 2026

Gross proceeds

Price per share

Shares issued
Warrant coverage
Placement agent
Filing link and full terms

Offering

Issued 2026

Gross proceeds

Price per share

Shares issued
Warrant coverage
Placement agent
Filing link and full terms

ATM block sale

Gross proceeds

Price per share

Shares issued
Warrant coverage
Placement agent
Filing link and full terms

Know who's about to sell into your ARCT trade

Exercise prices, conversion terms, shelf headroom and the filing sentence behind every number.

Get Pro · every ticker

From $29.99/mo. Signal8 Pro is $49/mo, or $40.67/mo billed yearly ($488/yr)

DilutionScanEvery instrument in full · From $29.99/mo